Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature

Hye Won Lee, Moon Jae Chung, Huapyong Kang, Heun Choi, Youn Jeong Choi, Kyung Joo Lee, Seung Woo Lee, Seung Hyuk Han, Jin Seok Kim, Si Young Song

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalGut and liver
Volume8
Issue number1
DOIs
Publication statusPublished - 2014 Jan

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature'. Together they form a unique fingerprint.

  • Cite this